Fig. 1 · Structure

Documents & Downloads

CD 437

Cat. No. A11793 CAS 125316-60-1

RARγ-selective agonist

CD 437 is a synthetic retinoid that is an RARγ-selective agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HepG2 IC50 2.93 μM Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 32717483]
IGROV-1 IC50 0.35 μM Concentration of compound required for inhibition of (IGROV-1) human ovarian carcinoma cell growth by 50% [PMID: 16033272]
L02 IC50 10.08 μM Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 32717483]
NB-4 IC50 0.4 μM Concentration of compound required for inhibition of (NB4) human promyelocytic leukemia cell growth by 50% [PMID: 16033272]
QGY-7703 IC50 2.38 μM Antiproliferative activity against human QGY-7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 32717483]
SMMC-7721 IC50 5.25 μM Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 32717483]

CD 437 Research Summary

This section summarizes 2 in vitro studies of CD 437 from 2 published references. In vitro models include asynchronous HeLa cells; primary cortical neurons.

CD 437 In Vitro Studies

In asynchronous HeLa cells, CD 437 treatment resulted in caspase-3 cleavage, assessed by immunoblotting. In primary cortical neurons undergoing OGD/ROG, increasing concentrations of AHPN produced statistically significant increases in viability and decreases in cell death compared with OGD/ROG without AHPN, as measured by FACS analysis. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Caspase cleavage in asynchronous HeLa cells

Cell-based study · asynchronous HeLa cells [1]

Asynchronous HeLa cells were treated with CD 437 at 5 μM for 8 hours. Immunoblotting showed cleavage of caspase-3.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
immunoblotting for caspase-3Reported result CD437 treatment of asynchronous HeLa cells resulted in the cleavage of caspase-3[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
8 hours
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: CD 437

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > POLA1 mutations cause CD437 resistance > CD437 toxicity is S-phase dependent (S63); Figure 3 legend (S186, S187)

immunoblotting for caspase-3: immunoblotting for caspase-3; comparator: DMSO — Results > POLA1 mutations cause CD437 resistance > CD437 toxicity is S-phase dependent (S63); Figure 3 legend (S187)

Neuronal viability during OGD/ROG

Cell-based study · primary cortical neurons [2]

Primary cortical neurons received AHPN during OGD/ROG. Compared with OGD/ROG without AHPN, increasing AHPN concentrations produced statistically significant increases in viability and decreases in cell death measured by FACS analysis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell death after OGD/ROG as measured by FACS analysisReported result Increasing concentrations of AHPN displayed statistically significant increases in viability and decreases in cell death after OGD/ROG as measured by FACS analysis.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
5 h OGD followed by 16 h ROG
Method
during OGD/ROG
Vehicle
0.1% DMSO
Co-treatment
Other interventions in this design: OGD/ROG. Compound effect isolated by the comparison: compared with OGD/ROG without AHPN.
Methods and source locations

Compound reported in the paper: CD 437; Compound label in the paper: AHPN

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > OGD and the assessment of cell death (S39); Results > qHTS identified active compounds are capable of inducing protection against oxygen/glucose deprivation (OGD)/restoration of oxygen/glucose (ROG) (S92, S93); Figure 5. legend (S137, S141, S142, S144)

cell death after OGD/ROG as measured by FACS analysis: cell death after OGD/ROG as measured by FACS analysis; comparator: OGD/ROG without AHPN — Figure 5. legend (S141)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 125316-60-1
Applications RARγ-selective agonist
Formula C27H26O3
Molecular Weight 398.5
Synonyms AHPN
SMILES
C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

CD 437 Research References

  1. [1] Han T, Goralski M, Capota E, et al. The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α. Nat Chem Biol (2016). PMID: 27182663 DOI: 10.1038/nchembio.2082 Source material
  2. [2] Bernstock JD, Lee YJ, Peruzzotti-Jametti L, et al. A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. J Cereb Blood Flow Metab (2016). PMID: 26661196 DOI: 10.1177/0271678X15609939 Source material

Added to your cart

View Cart Checkout
Loading...